Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469226 | 0.88 | ABCG2 (0.40) | ABCG2TP53MAPTPOLBRAD52 | |
| Trifluoroacetic Acid SCHEMBL6466277 | 0.85 | ABCG2 (0.40) | ABCG2TP53MAPTPOLBRAD52 | |
| SCHEMBL6468667 | 0.83 | TP53 (0.40) | ABCG2TP53MAPTPOLBMEN1 | |
| SCHEMBL6466280 | 0.82 | KMT2A (0.37) | ABCG2TP53MAPTPOLBRAD52 | |
| SCHEMBL6468661 | 0.82 | BRAF (0.39) | ADORA2A | |
| SCHEMBL6470324 | 0.82 | TP53 (0.42) | ABCG2TP53MAPTPOLBRAD52 | |
| SCHEMBL6468599 | 0.81 | ADORA2A (0.37) | ABCG2TP53MAPTPOLBRAD52 | |
| SCHEMBL6467193 | 0.81 | ABCG2 (0.40) | ABCG2TP53MAPTPOLBRAD52 | |
| SCHEMBL6469862 | 0.80 | KMT2A (0.35) | ABCG2MAPTPOLBKMT2AADORA2A | |
| SCHEMBL6471223 | 0.79 | MTNR1A (0.40) | TP53MAPTPOLBRAD52MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005030131-A2 | BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | REPLIDYNE, INC (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | ABCG2 1526/4885TP53 1339/4885MAPT 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.